SCHEMBL3689623

SCHEMBL3689623

O=C(O)c1nc2c(C(F)(F)F)cc(-c3ccccc3)cn2c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LDHA P00338 3/20 0.43
HDAC6 Q9UBN7 1/20 0.38
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
NPC1 O15118 1/20 0.36
NFKB1 P19838 1/20 0.36
RAB9A P51151 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
TP53 P04637 1/20 0.36
RORC P51449 1/20 0.36
KMT2A Q03164 2/20 0.36
POLB P06746 2/20 0.36
MDM2 Q00987 1/20 0.35
KDM4E B2RXH2 3/20 0.35
DHODH Q02127 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3694706 0.90 SMN1; SMN2 (0.44) LDHAALDH1A1SMN1; SMN2NPC1NFKB1
SCHEMBL3692564 0.90 MARS1 (0.39) SMN1; SMN2DHODHKMO
SCHEMBL3787142 0.90 KMO (0.36) LDHAKMOL3MBTL1
SCHEMBL3689791 0.90 PIN1 (0.41) LDHAALDH1A1KDM4EDHODHKMO
SCHEMBL3703173 0.89 ERN1 (0.43) ALDH1A1GAAKDM4ELMNAKMO
SCHEMBL3696564 0.87 DHODH (0.38) LDHAHDAC6MAPTSMN1; SMN2NPC1
SCHEMBL3690057 0.86 LDHA (0.44) LDHAHDAC6ALDH1A1GAAMAPT
SCHEMBL3693270 0.86 PTGS1 (0.40) LDHASMN1; SMN2MDM2PIN1
SCHEMBL3686878 0.86 KMO (0.40) LDHASMN1; SMN2RORCKMO
SCHEMBL3691379 0.85 FTO (0.33) LDHAMAPTRORCKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
EP-2187883-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2010-05-26 EP disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 LDHA 512/4885HDAC6 746/4885ALDH1A1 1337/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 LDHA 512/4885HDAC6 746/4885ALDH1A1 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.